

Original papers, reports and research letters

To date I have written or co-written 95 original peer-reviewed papers, reports and research letters mostly on the topics of cholesterol and lipid metabolism, the clinical pharmacology of lipid regulating drugs, and clinical trial methodology.

ORIGINAL PAPERS AND REPORTS

1. **Gaw, A.**, Stewart, D.A. and Kesson, C.M.: Nocturnal hypoglycaemia: does the insulin regimen matter? *Annals of Clinical Biochemistry*. 24: 209-210, 1987.
2. **Gaw, A.**, McKean, C.M., Capps, N.E. and Glen, A.C.A.: Therapeutic drug monitoring: two heads are better than one. *Annals of Clinical Biochemistry*. 25: 214-215, 1988.
3. **Gaw, A.**, Griffin, B.A., Caslake, M.J., Collins, S.M., Lorimer, A.R., Packard, C.J., Shepherd, J.: Effects of acipimox on apolipoprotein B metabolism and low density lipoprotein subfraction distribution in hypercholesterolemic subjects. *Journal of Drug Development* 3 (Suppl. 1): 107-109, 1990.
4. Series, J.J., **Gaw, A.**, Kilday, C., Bedford, D.K., Lorimer, A.R., Packard, C.J., and Shepherd, J.: Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia. *British Journal of Pharmacology* 30: 49-54, 1990.
5. Griffin, B.A., Caslake, M.J., **Gaw, A.**, Sinnott, M., Yip, B. Packard, C.J., and Shepherd, J.: The effect of hypolipidaemic drugs on subfractions of plasma low density lipoprotein. *Atherosclerosis* 85: 93, 1990.
6. Lindsay, G.M., Bedford, D.K, **Gaw, A.**: Health promotion: passing the screen test. *Nursing Standard*. 6: 44-45, 1992.
7. **Gaw, A.**, Stewart, J.P., Pappu, A.S., Illingworth, D.R., Packard, C.J., and Shepherd, J.: Urinary mevalonic acid and plasma lathosterol: responses to simvastatin therapy. *Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease – 3rd Int. Symp. Munich 1990*, (Eds. Gotto, A.M., Jr., Mancini, M., Richter, W.O., and Schwandt, P.) 1992, 287-291, Karger, Basel.
8. **Gaw, A.**, Lindsay, G.M., Murray, E.F., Packard, C.J., Colquhoun I., Wheatley, D.J., Lorimer, A.R., Shepherd, J.: Mechanism of action of combined lipid lowering therapy in established coronary artery disease. *Circulation* 86(Suppl. I): I-159, 1992.
9. Griffin, B.A., Caslake, M.J., **Gaw, A.**, Yip, B., Packard, C.J., Shepherd, J.: Effects of cholestyramine and acipimox on subfractions of plasma low density lipoprotein. Studies in normolipidaemic and hypercholesterolaemic subjects. *European Journal of Clinical Investigation* 22: 383-390, 1992.
10. **Gaw, A.**, Wosornu, D.: Simvastatin during warfarin therapy in hyperlipoproteinaemia. *Lancet* 340: 979-980, 1992.
11. Demant, T., **Gaw, A.**, Watts, G.F., Durrington, P., Buckley, B., Imrie, C.W., Wilson, C., Packard, C.J., and Shepherd, J.: Metabolism of apoB-100-

containing lipoproteins in familial hyperchylomicronemia. *Journal of Lipid Research* 34: 147–156, 1993.

12. **Gaw, A.**, Packard, C.J., Murray, E.F., Lindsay, G.M., Griffin, B.A., Caslake, M.J., Vallance, B.D., Lorimer, A.R., and Shepherd, J.: Effects of simvastatin on apoB metabolism and LDL subfraction distribution. *Arteriosclerosis and Thrombosis* 13: 170–189, 1993.
13. Caslake, M.J., Packard, C.J., **Gaw, A.**, Murray, E.F., Griffin, B.A., Vallance, B.D., and Shepherd, J.: Fenofibrate and low density lipoprotein metabolic heterogeneity in hypercholesterolemia. *Arteriosclerosis and Thrombosis* 13: 702-711, 1993.
14. Packard, C.J., Lindsay, G.M., **Gaw, A.**, and Taskinen, M.R.: Thyroid replacement therapy and its influence on post-heparin plasma lipases and apolipoprotein B metabolism in hypothyroidism. *Journal of Clinical Endocrinology and Metabolism*. 76: 1209-1216, 1993.
15. **Gaw, A.**, Packard, C.J., Caslake, M.J., Griffin, B.A., Lindsay, G.M., Thomson, J., Vallance, B.D., Wosornu, D, and Shepherd, J.: Effects of ciprofibrate on LDL metabolism in man. *Atherosclerosis* 108: 137-148, 1994.
16. **Gaw, A.**, Boerwinkle, E., Cohen, J.C., and Hobbs, H.H.: Comparative analysis of the apo(a) gene, apo(a) glycoprotein and plasma concentrations of Lp(a) in three ethnic groups - evidence for no common "null" allele at the apo(a) locus. *Journal of Clinical Investigation* 93: 2526-2534, 1994.
17. Lindsay, G.M., Christie, J. **Gaw, A.**, Packard, C.J. and Shepherd, J.: Educating children about heart disease. *Nursing Standard* 8: 32-35, 1994.
18. **Gaw, A.**, Packard, C.J., Lindsay, G.M., Griffin, B.A., Caslake, M.J., Lorimer, A.R., and Shepherd, J.: Overproduction of small very low density lipoproteins (Sf 20-60) in primary moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. *Journal of Lipid Research* 36: 158-171, 1995.
19. Packard, C.J., **Gaw, A.**, Demant, T. and Shepherd, J: Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism. *Journal of Lipid Research* 36: 172-187, 1995
20. Lindsay, G.M., Robb, A.J.P., and **Gaw, A.**: The practice nurse in coronary heart disease screening: fitting the role. *Nursing Standard* 9: 28-30, 1995.
21. Lindsay, G.M. and **Gaw, A.** Secondary prevention of coronary heart disease in practice. *Physiotherapy* 81: 398, 1995.
22. **Gaw, A.**, Mancini, F.P., and Ishibashi, S. Rapid genotyping of low density lipoprotein receptor knock-out mice using a polymerase chain reaction technique. *Laboratory Animal* 29: 447-449, 1995.
23. **Gaw, A.**, Lindsay, G.M., Shepherd, J. and Hutton, I. Shared-care prevention of coronary heart disease. *Prescriber* December, 33-42, 1995.

24. Lindsay, G.M., Tait, G.W., Lorimer, A.R., Shepherd, J., Carter, D.E., Smith L.N. and **Gaw, A.** Modifying cardiovascular risk-factors after CABG. *Audit in General Practice* 3: 13-17, 1995.
25. Lindsay, G.M., Hinnie, J., and **Gaw, A.** Setting up a helpline on heart disease. *Nursing Standard* 10: 27-30, 1995.
26. **Gaw, A.** and Chiesa, G.C. Characterization of commercial monoclonal antibodies used in high resolution apolipoprotein (a) phenotyping by immunoblotting. *Clinica Chimica Acta* .240: 75-81 1995.
27. **Gaw, A.**, Packard, C.J., Lindsay, G.M., Collins, S., Lorimer, A.R., and Shepherd, J. Metabolism of apolipoprotein B in primary moderate hypercholesterolemia: effects of acipimox and cholestyramine therapy. *European Journal of Medical Research* 1: 38-48, 1995.
28. Sattar, N., Lindsay, G.M., Paterson K., and **Gaw, A.** Coronary disease in British South Asians. *Practice Nursing* 7: 22-24, 1996.
29. Wray, R., Neil, A., Rees, A., on behalf of the National Committee of the British Hyperlipidaemia Association (Betteridge, D.J., Dominiczak, M.H., Durrington, P.N., Elkeles, R.S., **Gaw, A.**, Hughes, E.A., Neil, H.A.W., Nichols, D.P., Packard, C., Rees, J.A.E., Richmond, W., Seed, M., Wray, R.). Screening for hyperlipidaemia in childhood. Recommendations of the British Hyperlipidaemia Association. *Journal of the Royal College of Physicians* 30: 115-118, 1996.
30. **Gaw, A.**, Lindsay, G.M., Murray, E. F., Caslake, M.J., Griffin, B.A., Packard, C.J., Colquhoun, I., Wheatley, D. J., Lorimer, A.R. and Shepherd, J.: Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. *Arteriosclerosis, Thrombosis and Vascular Biology* 16: 236-249, 1996.
31. Sattar, N., **Gaw, A.**, Packard, C.J. and Greer, I.A. Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre-eclampsia. *British Journal of Obstetrics and Gynaecology*. 103: 614-620, 1996.
32. **Gaw, A.** Can the clinical efficacy of HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? *Atherosclerosis*. 125: 267-269, 1996.
33. **Gaw, A.**, Lindsay, G.M., Ford, I.: Coronary disease prevention: a study. *Practice Nursing* 7: 36-38, 1996.
34. Cohen J., **Gaw, A.**, Barnes R.I., Landschulz, K. and Hobbs, H.H. Genetic factors that contribute to interindividual variations in plasma low density lipoprotein cholesterol levels. *Ciba Foundation Symposium*, 197: 194-210, 1996.
35. Lindsay, G.M. and **Gaw, A.** The study day: short course or short change? *Nursing Times* 93: 39-41, 1997.
36. **Gaw, A.**, Gourlay, C.W.D., Brown, E.A. and Bell, M.A. Evaluation of a new automated latex agglutination assay for lipoprotein (a): comparison with a manual ELISA. *Clinica Chimica Acta* 261: 175-183, 1997.

37. **Gaw, A.**, Brown, E.A. and Ford, I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. *Arteriosclerosis, Thrombosis and Vascular Biology* 18: 1870-1876, 1998.
38. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society. Joint British Recommendations on prevention of coronary heart disease in clinical practice. *Heart* 80(supplement): S1-S29, 1998.
39. **Gaw, A.**, Docherty, G., Brown, E.A. and Ford, I. Predictors of plasma lipoprotein(a) concentration in the West of Scotland Coronary Prevention Study cohort. *Atherosclerosis* 143: 445-450, 1999.
40. **Gaw, A.**, Docherty, G., Brown, E.A. and Ford, I. Use of the West of Scotland Coronary Prevention Study bio-bank to provide new insights into the control of plasma lipoprotein(a) concentrations. *Biochemical Society Transactions* 27: 459-463, 1999.
41. Shepherd, J., Blauw, G.J., Murphy, M.B., Cobbe, S.M., Bollen, E., Buckley, B.M., Ford, I., Jukema, J.W., Hyland, M., **Gaw, A.**, Lagaay, M., Perry, I.J., Macfarlane, P.W., Meinders, A.E., Sweeney, B., Packard, C.J., Westendorp, R., Twomey, C., Stott, D. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). *American Journal of Cardiology* 84: 1192-1197, 1999.
42. **Gaw, A.**, Docherty, G., Brown, E.A. and Ford, I. Is lipoprotein (a)-cholesterol a better predictor of vascular disease events than total lipoprotein (a) mass ? A nested case control study from the West of Scotland Coronary Prevention Study. *Atherosclerosis* 148: 95-100, 2000.
43. **Gaw, A.**, Brown, E.A., Gourlay, C.W.D., Bell, M.A. Analytical performance of the Genzyme LipoPro Lp(a) kit for plasma lipoprotein(a)-cholesterol assay. *British Journal of Biomedical Science* 57: 13-18, 2000.
44. Cuchel M, Stott DJ, **Gaw A.**, Vergani C., Packard C.J. Atherogenic lipid profile in elderly patients with ischaemic cerebrovascular disease: total cholesterol levels may be misleading. *Lancet* 356: 401-402, 2000.
45. Freeman DJ, Norrie J, Sattar N, Neely DG, Stuart M, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J and **Gaw A.** Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. *Circulation* 103: 357-362, 2001.
46. Wallace, A.M., McMahon, A.D., Packard, C.J., Kelly, A., Shepherd, J., **Gaw, A.**, Sattar, N. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study. *Circulation* 2001 104: 3052-3056.
47. Freeman DJ, Norrie J, Caslake, M.J., **Gaw, A.**, Ford I, Lowe GDO, O'Reilly D StJ, Packard CJ, and Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes mellitus in the West of Scotland Coronary Prevention Study. *Diabetes* 2002, 51: 1596-1600.
48. Houx, P.J., Shepherd, J., Blauw, G.J., Murphy, M.B., Ford, I., Bollen, E., Buckley, B.M., Stott, D., Jukema, J.W., Hyland, M., **Gaw, A.**, Kamper, A.M.

- Perry, I.J., Macfarlane, P.W., Meinders, A.E., Sweeney, B., Packard, C.J., Twomey, C., Cobbe, S.M. Westendorp, R. Testing cognitive function in elderly populations: the PROSPER Study. *Journal of Neurology, Neurosurgery and Psychiatry*, 2002, 73: 385-389.
49. Avorn J., Benner, J., Ford, I., Ganz, D.A., **Gaw, A.**, Glynn, R.J., Jackson, J., Lagaay, A.M., Schneeweiss, S., Walley T., Wang, P.S. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER Trial. *Current Controlled Clinical Trials* 2002, 23: 757-773.
 50. Belcher, P.R., **Gaw, A.**, Cooper, M., Brown, M., Wheatley, D.J., Lindsay, G.M. Are we negating the benefits of CABG by forgetting secondary prevention? *Journal of Human Hypertension* 2002, 16: 691-697.
 51. Ford, I., Blauw, G.J., Murphy, M.B., Shepherd, J., Cobbe, S.M., Bollen, E., Buckley, B.M., Jukema, J.W., Hyland, M., **Gaw, A.**, Lagaay, A.M., Perry, I.J., Macfarlane, P.W., Norrie, J., Meinders, A.E., Sweeney, B., Packard, C.J., Westendorp, R., Twomey, C., Stott, D. Baseline results of the prospective study of pravastatin in the elderly at risk (PROSPER). *Current Controlled Trials in Cardiovascular Medicine* 2002, 3: 8.
 52. Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L.E.M., Buckley, B.M Cobbe, S.M.,, Ford, I., **Gaw, A.**, Hyland, M., Jukema, J.W., Kamper, A.M., Macfarlane, P.W., Meinders, A.E., Norrie, J., Packard, C.J., Perry, I.J., Stott, D.J., Sweeney, B.J., Twomey, C., Westendorp, R.G.J. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 360: 1623-30, 2002.
 53. Sattar N, **Gaw A**, Scherbakova O, Ford I, O'Reilly D St J, Haffner SM, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in West of Scotland Coronary Prevention Study. *Circulation*, 108: 414-419, 2003.
 54. Tolmie, E.P., Lindsay G.M., Kerr, S.M., Brown, M.R., Ford, I., **Gaw A.** Patients' perspectives on statin therapy for treatment of hypercholesterolaemia: a qualitative study. *European Journal of Cardiovascular Nursing*, 2: 141-149, 2003.
 55. Tolmie, E., Mungall, M.M.B., Louden G, Lindsay, G.M. **Gaw A.** Understanding why older people participate in clinical trials: the experience of the Scottish PROSPER participants. *Age and Ageing* 33: 374-378, 2004.
 56. Ronald ES, Dinnett EM, Kent JA, Mungall MMB, **Gaw A.** Dealing with visually impaired patients participating in a clinical trial. *Good Clinical Practice Journal* 11: 17-19, 2004.
 57. Dinnett EM, Mungall MMB, Kent JA, Ronald ES, **Gaw A.** Closeout of a major clinical trial: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). *Clinical Trials* 1: 545-552, 2004.
 58. Ronald ES, Dinnett EM, Kent JA, Mungall MMB, Gaw A, on behalf of the PROSPER Study Group. Videoconferencing – its usefulness in clinical trials. *Clinical Research Focus* 15: 31-33, 2004.

59. van den Heuvel DMJ, Admiraal-Behloul F, ten Dam VH, Olofsen H, Bollen ELEM, Murray HM, Blauw GJ, Wesendorp RGJ, de Craen AJM, van Buchem MA for the **PROSPER Study Group**. Different progression rates for deep white matter hyperintensities in elderly men and women. *Neurology* 63: 1699-1701, 2004.
60. ten Dam, V.H., van den Heuvel, M.J., van Buchem, M.A., Westendorp, R.G.J., Bollen, E.L.E.M., Ford, I., de Craen, A.M., Blauw, G.J., and the **PROSPER Study Group**. Effect of pravastatin on cerebral infarcts and white matter lesions. *Neurology* 64: 1807-1809, 2005.
61. Dinnett EM, Mungall MMB, Kent JA, Ronald ES, Anderson E, **Gaw A**. Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). *Clinical Trials* 2: 254-259, 2005.
62. **Gaw A**, Murray HM, Brown EA for the PROSPER Study Group. Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). *Atherosclerosis* 180: 381-388, 2005.
63. ten Dam VH, Box FMA, de Craen AJM, van den Heuvel DMJ, Bollen ELEM, Murray HM, van Buchem MA, Wetsendorp RGJ, Blauw GJ for the **PROSPER Study Group**. Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in the elderly at risk for vascular disease. *Stroke* 36: 1633-1636, 2005.
64. Packard CJ., Ford I, Robertson M, Shepherd J, Blauw GJ., Murphy MB., Bollen ELEM, Buckley BM, Cobbe SM, **Gaw A**, Michael Hyland M, Jukema, JW, Kamper AM., Macfarlane PW, Perry IJ., Stott DS, Sweeney BJ, Twomey C, Westendorp, RGJ., for the PROSPER Study Group. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). *Circulation* 112: 3058-3065, 2005.
65. Kamper AM, Stott DJ, Hyland MH, Murray HM, Ford, I for the **PROSPER study group**, Predictors of functional decline in elderly people with vascular risk factors or disease. *Age and Ageing* 34: 450-455, 2005.
66. Fellström, B, Faiez Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W and the **AURORA Study Group**. Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. *Current Controlled Trials in Cardiovascular Medicine* 2005, 6:9.
67. Langer A, **Gaw A**, de Teresa E, Farsang C, Gensini GF, Leiter LA, Martineau P. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) Study. *Atherosclerosis* Apr 25, 2006 [Epub ahead of print]
68. Versluis CE, van der Mast, RC, van Buchem, MA, Blauw GJ, Eekhof, JAH, NJAMD, de Craen, AJM for the **PROSPER study group**. Progression of cerebral white matter lesions is not associated with depressive symptoms in

- elderly subjects at risk of cardiovascular disease. The PROSPER Study. *International Journal of Geriatric Psychiatry* 21: 375-381, 2006.
69. van den Heuvel, DMJ, ten Dam, VH, de Craen, AJM, Admiraal-Behloul, F, van Es, ACGM, Palm, WM, Spilt, A, Bollen, ELEM, Blauw, GJ, Launer, L, Westendorp, RGJ, van Buchem, MA. On behalf of the **PROSPER study group**. Measuring longitudinal white matter changes: comparison of a visual rating scale with a volumetric measurement. *American Journal of Neuroradiology* 27: 875-878, 2006.
 70. van den Heuvel, ten Dam, VH, DMJ, de Craen, AJM, Bollen, ELEM, Murray HM, Westendorp, RGJ, Blauw, GJ, van Buchem, MA. On behalf of the **PROSPER study group**. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. *Journal of Neurology, Neurosurgery and Psychiatry* 77: 149-153, 2006.
 71. Gordon MC, Ronald ES, Dinnett EM, **Gaw A**, Mungall MMB. A means to an endpoint. October, 25-29. *Good Clinical Practice Journal* 13: 25-29, 2006.
 72. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, **Gaw A**, Gensini G, Leiter LA, Langer A, Martineau P, Hernandez G, Egido J; ACTFAST investigators. Increased soluble Fas plasma levels in subjects at high cardiovascular risk. Atorvastatin on Inflammatory Markers (AIM) study, a sub-study of ACTFAST. *Arteriosclerosis, Thrombosis and Vascular Biology* 27: 168-74, 2007.
 73. Packard CJ., Westendorp, RGJ., Caslake, MJ., Murray HM, Shepherd J, Blauw GJ., Murphy MB., Bollen ELEM, Buckley BM, Cobbe SM, Ford I, **Gaw A**, Michael Hyland M, Jukema, JW, Kamper AM., Macfarlane PW, Jolles J, Perry IJ., Stott DS, Sweeney BJ, Twomey C, for the PROSPER Study Group. Impact of apolipoprotein E4 and lipoproteins on cognitive impairment in the elderly. *Journal of the American Geriatric Society (JAGS)* 55: 1777-85, 2007.
 74. Trompet S, Pons D, de Craen AJM, Slagboom PE, Shepherd, J., Blauw, G.J., Murphy, M.B., Cobbe, S.M., Bollen, E.L.E.M., Buckley, B.M Ford, I., Hyland, M., **Gaw, A.**, Macfarlane, P.W., Packard, C.J., Norrie, J., Kamper, A.M., Perry, I.J., Stott, D.J., Sweeney, B.J., Twomey, C., Westendorp, R.G.J., Jukema, J.W. Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events. The PROSPER study. *Annals of the New York Academy of Sciences*, 1100; 189-98, 2007.
 75. Sattar N; Murray HM; Blauw GJ; Bollen ELEM; Buckley BM; Cobbe SM; Ford I; **Gaw A**; Hyland M; Jukema JW; Kamper AM; Macfarlane PW, Murphy MB; Packard; Ivan J. Perry; Stott DJ; Sweeney BJ; Twomey C; Westendorp RGJ; Shepherd J; for the PROSPER Study Group. CRP and prediction of vascular events in PROSPER. *Circulation* 115; 981-9. 2007.
 76. Sattar N; McConnachie A; Ford I; **Gaw A**; Cleland S; Forouhi NG; Macfarlane PW; Shepherd J; Cobbe SM; Packard CJ. Serial metabolic measurements and conversion to type 2 diabetes in WOSCOPS: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. *Diabetes*, 56(4):984-91, 2007.
 77. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, **Gaw A**, Gensini G, Leiter LA, Langer A, Martineau P, Egido J. ACTFAST investigators. Elevated

- ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. *American Heart Journal* 153(5):881-8, 2007.
78. Farsang C, Athyros VG, **Gaw A**, et al. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) Study. *Current Medical Research and Opinion*, 8: 1945-56, 2007.
 79. Leiter LA, Martineau P, de Teresa E, Farsang C, **Gaw A**, Gensini GF, Langer A. Targeted dosing of atorvastatin achieves cholesterol targets quickly in subjects with diabetes or the metabolic syndrome (the ACTFAST studies). *Journal of Family Practice*, 57: 661-668, 2008.
 80. Freeman DJ, Robertson M, Brown EA, Rumley A, Tobias E, Ford I, **Gaw A**, Greer IA, Lowe GD, Stott DJ. Risk factors for the development of incident venous thrombotic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Submitted to *Journal of Thrombosis and Haemostasis*, 2008.
 81. Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, **Gaw A**, Gensini GF, Leiter LA, Langer A, Martineau P, Egido J. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. *European Journal of Pharmacology*, 586:259-265, 2008.
 82. Trompet S, de Craen AJM, Slagboom PE, Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L.E.M., Buckley, B.M Ford, I., **Gaw, A.**, Macfarlane, P.W., Packard, C.J., Stott, D.J., Jukema, J.W., Westendorp, R.G.J. and on behalf of the PROSPER Group. Genetic variation in the interleukin-1 beta converting enzyme associates with cognitive function. The PROSPER study. *Brain*, 131:1069-77, 2008.
 83. Trompet S, de Craen AJM, Slagboom PE, Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L.E.M., Buckley, B.M Ford, I., **Gaw, A.**, Macfarlane, P.W., Packard, C.J., Stott, D.J., Westendorp, R.G.J., Jukema, J.W. Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study. *Experimental Gerontology* 43:801-805, 2008.
 84. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, **Gaw A**, Gensini GF, Leiter LA, Langer A, Martineau P, Egido J. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. *Kidney International*, Suppl. 111:S60-3, 2008.
 85. Gensini GF, Gori AM, Di Laghi B, Rostagno C, **Gaw A**, Blanco-Colio LM, de Teresa E, Egido J, Farsang C, Leiter LA, Martineau P, Nozza A, Langer A, on behalf of the ACTFAST investigators. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) Study. In press: *International Journal of Cardiology*, 2009.

86. Lindsay GM, Niven KA, Brodie EE, **Gaw A**, Belcher P. Accuracy of patient recall of pre-operative symptom severity at one year following coronary artery bypass grafting. *Journal of Clinical Nursing*, 18: 418-25, 2009.

RESEARCH LETTERS

1. **Gaw, A.**: A prospective study of lipoprotein (a) and the risk of myocardial infarction. *JAMA* 271: 1077, 1994.
2. Sattar, N. and **Gaw, A.** Risk of coronary heart disease in Asian women. *British Medical Journal* 310: 466-467 1995.
3. Sattar, N. and **Gaw, A.** The mineralocorticoid effects of high dose hydrocortisone. *British Medical Journal* 311: 260, 1995.
4. Bollen EL, **Gaw, A.**, Buckley, B.M. Statin therapy and the prevention of dementia. *Archives of Neurology* 58: 1023-1024, 2001.
5. Blauw GJ, Shepherd J, Murphy MB for the **PROSPER Study Group**. Dementia and statins. PROSPER Study. *Lancet* 357:881, 2001
6. Shepherd J, Blauw GJ, Murphy MB, on behalf of the **PROSPER** investigators. The PROSPER Trial - correspondence – Authors' reply. *Lancet* 361: 9355, 2003.
7. Shepherd J, Blauw GJ, Murphy MB, on behalf of the **PROSPER** investigators. More on PROSPER - correspondence – Authors' reply. *Lancet* 361:1135-1136, 2003.
8. **Gaw, A.** and Mungall, M.M.B. New European clinical trials directive. Implementation requires funding for effective training programmes. *British Medical Journal* 328: 522, 2004.
9. Dinnett EM, Mungall MM, Gordon C, Ronald ES, **Gaw A**. Offering results to research participants. *British Medical Journal* 332:549-50, 2006.